AIM Immunotech Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AIM Immunotech Inc. (AIM) on September 14, 2026, covering events that occurred on September 8 and September 9, 2026. The filing details a material definitive agreement involving the conversion of debt into equity.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The specific financial activity reported is:
- Debt Conversion: Approximately $400,000 of a Promissory Note dated November 18, 2025, was converted into equity.
- Equity Issuance: 1,749,434 shares of common stock were issued to Streeterville Capital, LLC.
- Conversion Price: The average conversion price was approximately $0.228 per share.
Material Changes
The primary material change is the reduction of outstanding debt and the corresponding increase in outstanding common shares. This transaction was executed pursuant to two Exchange Agreements and Partitioned Promissory Notes with Streeterville Capital, LLC. The conversion was previously approved by stockholders at a special meeting held on July 15, 2026, in compliance with NYSE American Company Guide Sections 713(a) and 713(b).
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the transaction. The issuance of the Exchange Shares was made pursuant to the exemption from registration requirements under Section 3(a)(9) of the Securities Act of 1933, as no commission was paid for soliciting the exchange.
Investor Verification Checklist
- Verify the total number of outstanding shares post-conversion to assess dilution impact.
- Review the full text of the Exchange Agreement (Exhibit 10.1) for any remaining debt obligations or covenants.
- Confirm the status of the remaining balance of the Promissory Note dated November 18, 2025, if any.
- Check subsequent filings for any changes in the company's liquidity position following this debt-to-equity swap.